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AbstrACt
Introduction Problematic benzodiazepine use is a global 
health issue. Although the adverse side effects of long- 
term use of benzodiazepines are well known, it remains 
difficult to implement interventions for discontinuation in 
primary care. Considering the success of blended care 
for the treatment of sleeping disorders and the support of 
substance use disorders, evidence suggests that a blended 
care approach, combining face- to- face consultations with 
the general practitioner with web- based self- learning by 
the patient, is beneficial for the discontinuation of chronic 
benzodiazepine use for primary insomnia in general 
practice. Therefore, the aim of this study is to evaluate the 
effectiveness of such an approach for the discontinuation 
of benzodiazepine and zolpidem, zopiclone and zaleplon 
drugs ((z- )BZD) use in the long term and evaluate the 
implementation process.
Methods and analysis This study is a multicentre, 
pragmatic, cluster randomised controlled trial with 1200 
patients, included by 120 general practitioners. Allocation 
to usual or blended care happens at the level of the 
general practice in a 1:1 ratio using a block randomisation 
system stratified per language. The study population 
consists of adult primary care patients who have been 
using (z- )BZD for primary insomnia on a daily basis for at 
least 6 months. Primary outcome measure is the proportion 
of patients that discontinued (z- )BZD at 12 months 
assessed by toxicological screening for (z- )BZD in urine. 
Secondary outcomes include discontinuation of (z- )BZD at 
6 months, quality of life and the number of defined daily 
doses of (z- )BZD prescribed. Data will be collected using 
a study- specific online platform and analysed using the 
intention- to- treat approach. The process of implementing 
blended care will be evaluated in a nested study.
Ethics and dissemination This trial was approved by 
the Ethics Committee for Research of UZ/KU Leuven 
(ref. S61194). Study results will be disseminated via 
open- access, peer- reviewed publications and conference 
presentations.
trial registration number NCT03937180.
IntroduCtIon
background
Worldwide, benzodiazepines and the related 
hypnotic drugs zolpidem, zopiclone and zale-
plon ((z- )BZD) are prescribed extensively to 
strengths and limitations of this study
 ► To the authors’ best knowledge, this is the first ran-
domised controlled trial to evaluate the effective-
ness of an online intervention on benzodiazepine 
deprescribing in general practice.
 ► The use of toxicological screening of urine samples, 
self- report on discontinuation of benzodiazepine and 
zolpidem, zopiclone and zaleplon use, and number 
of defined daily doses prescribed will provide valu-
able insights with regard to the efficacy of the inter-
vention and the reliability of the use of self- reporting 
in similar studies.
 ► To optimise the generalisability of the findings, this 
is a multicentre study with participants from both 
Dutch- speaking and French- speaking parts of 
Belgium.
 ► The focus is on the effect of blended care, but the 
implementation of such an approach is also eval-
uated, which will provide valuable knowledge for 
further eHealth developments in primary care.
 ► Non- e- literate patients are excluded from the study, 
even though this vulnerable group of patients could 
also benefit from more psychosocial support and 
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Figure 1 Flow chart of trial design summary.
treat anxiety and sleeping disorders, and used as adjuvant 
therapy in depression, pain management and as muscle 
relaxants. Recommendations state that treatment with 
(z- )BZD should be limited to only a few weeks. Despite the 
fact that long- term- use is ineffective and also associated 
with adverse side effects, the prevalence of long- term use, 
which is most common for sleeping disorders, remains 
widespread.1–11 A recent systematic review summarising 
current evidence- based discontinuation strategies indi-
cates that gradual tapering of doses is an effective (z- )
BZD discontinuation intervention for adult patients with 
long- term (z- )BZD use.12 However, a combination of dose- 
tapering and non- pharmacological interventions such as 
psychotherapy interventions, self- help instructions and 
patient education produces better outcomes compared 
to stand- alone strategies.13 14
With the growing use of internet, e- based approaches 
are becoming more popular. Among them, blended care, 
defined as a combination of care by applying an inter-
active educational e- tool in combination with face- to- face 
clinical consultations with the care provider, is a new and 
promising approach.15 16 Blended care has already proven 
to be successful in treating sleeping disorders, supporting 
substance use disorders, in stress management for 
employees, treating depression and other psychiatric and 
somatic conditions.17–21
In 2015, a small descriptive pilot study suggested that 
blended care for the discontinuation of (z- )BZD use for 
sleeping disorders may be more effective than a minimal 
intervention, such as a discontinuation letter or discon-
tinuation advice, and as effective as face- to- face inter-
ventions combining tapering protocols and education.22 
Because these findings need to be confirmed by a prop-
erly powered and controlled study, a multicentre cluster 
randomised trial was designed, supported by the Belgian 
Federal Knowledge Centre for Healthcare (KCE) Trials 
programme.
This study aims to establish an evidence- based blended 
care approach for the discontinuation of chronic (z- )BZD 
use for a primary indication of sleeping disorders in adult 
patients in a primary care setting. We hypothesise that 
blended care will support general practitioners as it is less 
time- consuming and that it will empower patients to take 
a more active role in their discontinuation process. In that 
way, we think it may increase their motivation, which may 
result in increased discontinuation of (z- )BZD and more 
long- term discontinuation than currently with usual care.
objectives
The primary objective is to compare the effect of blended 
care versus usual care on the proportion of subjects that 
has discontinued (z- )BZD use 12 months after start of 
the intervention as assessed by toxicological screening, 
in a population of adult primary care patients chron-
ically using (z- )BZD for a primary indication of sleeping 
disorders.
Secondary objectives are to compare the effect of 
blended versus usual care on:
1. The discontinuation of (z- )BZD use 6 months after 
start of the intervention, as assessed by toxicological 
screening.
2. The quality of life assessed by e- questionnaire at week 
6, 12, 26 and 52.
3. The self- reported discontinuation of (z- )BZD use as-
sessed by e- questionnaire at week 6, 12, 26 and 52.
4. The number of defined daily doses (DDD) of (z- )BZD 
prescribed assessed by e- questionnaire at week 6, 12, 
26 and 52.
MEthods And AnAlysIs
study design and setting
This study is a multicentre, pragmatic, cluster randomised, 
controlled, superiority trial that will be performed in 
Belgian general practices. The participating general 
practitioners will be recruited voluntarily and monitored 
by the academic centres for general practice of the KU 
Leuven, UGent, UAntwerpen, ULiège, Université Libre 
de Bruxelles and Vrije Universiteit Brussel. To participate, 
the general practice needs to be located in Belgium and 
treat the right patient population so it is feasible to recruit 
10 eligible patients within 6 to maximally 12 weeks. The 
cluster and unit of randomisation is the primary care prac-
tice. A 1:1 ratio will be used for allocation to the blended 
care arm and the usual care arm, as shown in figure 1.
The design of the study protocol has followed the recom-
mendations of the Standard Protocol Items: Recommen-
dations for Interventional Trials 2013 statement.23
Patient and public involvement
Patients were involved in several stages of the study. During 
a focus group with long- term (z- )BZD users the overall 
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of the e- tool, and the questionnaires and time required to 
complete them were discussed. Afterwards, these patients 
were also invited to provide written feedback on the 
informed consent form (ICF), patient information leaflet 
and patient information video. Moreover, during the user 
acceptance testing of the tool, we involved acquaintances 
with different health and e- literacy profiles that were 
not familiar with the trial. Finally, to assure continuous 
involvement of patients in the study, two long- term (z- )
BZD users are a member of the trial steering committee.
Eligibility criteria and recruitment
Patients’ eligibility for inclusion in the study will be based 
on the following criteria:
1. Aged 18 years and older, capable of giving informed 
consent.
2. Having his/her medical file managed by one of the 
participating general practitioners.
3. Receiving prescriptions of (z- )BZDs from participating 
general practitioner for use on a daily basis.
4. Reporting daily intake (≥80% of days) of (z- )BZDs in 
the last 6 months for a primary indication of sleeping 
problems.
Patients will be excluded from study participation based 
on the following criteria:
1. Presence of any severe psychiatric and neurological 
condition that in the judgement of the treating gener-
al practitioner implies a contraindication for (z- )BZD 
withdrawal.
2. Presence of terminal illness.
3. Any case where stopping of (z- )BZDs might be harm-
ful.
4. Unwillingness or inability to provide informed con-
sent.
5. Not having e- literacy (being familiar with email and 
internet use).
6. Patients with a substance use disorder (other than (z- )
BZD) will also be excluded from the study because in 
these cases there is often a subtherapeutic (z- )BZD de-
pendence and/or comorbid psychological/psychiatric 
comorbid conditions requiring specialist care.
Selection of eligible patients will be done consecu-
tively by the general practitioner during consultations. 
To inform the patients about the study a patient infor-
mation leaflet and video have been developed. When a 
patient is willing to participate, the general practitioner 
will obtain informed consent. The goal is to include 10 
patients within 6 to maximally 12 weeks.
sample size
Sample size calculation was based on a statistically 
significant difference in (z- )BZD discontinuation at 12 
months between intervention and control group of 10%, 
assuming a rate of discontinuation of 15% in the control 
group. This assumption is based on a systematic review by 
Mugunthan et al11 that shows us that usual care achieves a 
discontinuation rate of 10%–17%.
To further estimate the sample size, calculations were 
first based on findings from a similar study by Vicens 
et al,14 in which the drop- out rate after 12 months was 
7% and an overall intracluster correlation coefficient 
(ICC) of 0.03 was observed. However, a range in ICCs 
was observed, with an ICC of 0.109 in both intervention 
groups. (personal communication by funder with author) 
Therefore, the funder requested a more conservative 
approach which led to the use of 0.11 in this trial.
Assuming a drop- out rate of 10% and based on an alpha 
of 0.05% and 80% power, a total sample size of 594 patients 
(297 in each group) would be required for an individually 
randomised study. However, to account for clustering effects 
by primary care practices, we used an ICC set at 0.11 and a 
cluster size of 10 patients. The number of patients required 
was multiplied by 1.99 corresponding to the cluster design 
effect (DE=1+ ICC (size of the cluster-1)). Thus, the final 
sample will minimally consist of 1182 patients. Considering 
each general practitioner has to recruit 10 patients, 119 
general practitioners are needed. Because six academic 
centres for general practice are involved in the project, we 
aim at including 120 general practitioners in total.
random allocation
Within the week following the enrolment of the 10th 
patient (or a multiple of 10, depending on the number 
of participating general practitioners in that practice), 
the general practice is randomised in one of the two 
study arms in a 1:1 ratio using a block randomisation 
system stratified per language in order to guarantee 
that allocation to either usual care or blended care for 
the discontinuation of (z- )BZD is balanced between the 
Dutch- speaking and French- speaking community. To 
guarantee that the allocation process cannot be predicted 
two block sizes are used, four and six.
Using an electronic random numbers generator, two 
randomisation lists have been created, one for each 
language. After recruitment of the required number of 
patients, the project manager receives an e- mail alert 
that indicates the practice is ready for randomisation. 
The result of the allocation is communicated by e- mail to 
both the general practitioner(s) and the corresponding 
monitor.
blinding
General practitioners cannot be blinded to an interven-
tion that modifies their clinical practice. Because the 
researchers need to monitor the conduct of the study on 
site, they also cannot be blinded to the allocation of the 
general practitioners. Owing to study procedures, patients 
will neither be blinded. However, all involved parties are 
blinded to the allocation until after patient recruitment. 
Furthermore, the outcome assessors will be kept blinded 
to the allocation during the whole study until after data 
analysis.
Intervention
Patients in the usual care arm will receive care that is 
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They are expected to follow the Belgian guidelines, which 
propose education of the patient about the harmful 
effects of chronic (z- )BZD use, the alternatives and the 
advice to discontinue (z- )BZD use. A stepped approach 
is recommended. First, a minimal intervention strategy 
such as a discontinuation letter or a short advice is 
applied. If unsuccessful, a brief intervention, which may 
span one or more consults, is recommended. During such 
an intervention, the general practitioner will—based on 
the principles of motivational interviewing—assess the 
patient's readiness for change and match the appropriate 
intervention. Most likely, a tapering scheme is developed 
which typically consists of a 10%–20% reduction in the 
daily dose of (z- )BZD every two to four weeks.
For patients in the blended care arm, usual care is 
supported by the step- by- step use of an interactive e- tool. 
This tool consists of a sleeping diary, a tapering schedule 
and six modules, providing psychoeducation and medi-
cation education, which both focus on how to improve 
sleep. To gain access to all modules, patients have to open 
the sleeping diary and process module 1, where they eval-
uate their motivation to discontinue their (z- )BZD use. 
Based on the result, we offer them a customised sequence 
of modules to start with. However, at this time, they 
gain access to all modules and can freely choose which 
modules and how frequently they use the e- tool.
The psychoeducation modules contain tips and quizzes 
on sleep hygiene. The medication education explains how 
benzodiazepines and z- drugs work, and what their impact 
is on sleeping patterns. Both the pro’s and con’s of these 
types of medication are explained. Moreover, the e- tool 
contains exercises featuring cognitive behavioural tech-
niques to enhance the self- management of the patient. Its 
purpose is to motivate patients to discontinue the use of 
(z- )BZD, to adapt non- pharmacological remedies and to 
support them in this process.
The time of use will depend on the intensity of use, 
which is determined by the user, because certain exercises 
can be completed multiple times or updated, like the 
sleep hygiene evaluation or the sleeping diary. However, 
we estimate that processing all written information will 
take up to eight hours.
Patients can grant their participating general practi-
tioner access to all their answers in the e- tool, making 
it possible to discuss these findings and experiences 
face to face. During the consultations, the general 
practitioner will also assess the patients’ readiness for 
change and match the appropriate intervention, like a 
tapering scheme. Follow- up appointments are scheduled 
depending on the needs of the patient until the end of 
dose reduction.
At the moment, the e- tool is not publicly available since 
the control group cannot have access to it, in order to 
prevent contamination bias. The e- tool is located on a 
secure server and password protected so that only regis-
tered users can benefit from the content. However, 




The proportion of patients that discontinued (z- )BZD at 
12 months assessed by toxicological screening for (z- )BZD 
in urine.
Secondary outcome measures
1. The proportion of patients that discontinued use of 
(z- )BZD at 6 months assessed by toxicological screen-
ing for (z- )BZD in urine.
2. Quality of life assessed by EuroQol five dimension scale 
with three responses, EQ- 5D- 3L.24
3. Self- reported discontinuation of (z- )BZD.
4. The number of DDD of (z- )BZD prescribed.
Data will be collected either via questionnaires sent to 
the patient or by completion of the electronic case report 
form (eCRF) by the general practitioner, except for the 




At study entry, baseline data are collected using an e- ques-
tionnaire consisting of Alcohol Use Disorders Identi-
fication Test, Audit- C,25 EQ- 5D- 3L,24 Benzodiazepine 
Dependence Self- Report Questionnaire (BEDEQ),26 
Insomnia Severity Index (ISI)27 and European Health 
Literacy Survey, HLS- EU- Q16.28 All together this e- ques-
tionnaire comprises less than 50 questions.
Patients will also be requested to complete an abbrevi-
ated e- questionnaire at weeks 6, 12, 26 and 52 comprising 
of the validated EQ- 5D- 3L,25 Audit- C24 and Insomnia 
Severity Index. Furthermore, the e- questionnaire will 
register self- reported use of (z- )BZD and other psycho-
active medication, self- reported falls and use of medical 
services in the past period.
All e- questionnaires will consist of closed questions 
which are answered by ticking the appropriate box. Invi-
tations will be e- mailed to the study participants at week 5, 
11, 25 and 51 with the request to complete the question-
naires online within two weeks. A reminder will be sent 
after 1 week to all participants who have not yet responded 
and every week after, until response or the deadline. The 
deadline is set at 4 weeks after the first reminder for the 
questionnaires at week 6 and 12, and 8 weeks at week 26 
and 52.
Assessment by general practitioner
During the baseline visit, which will take place within 12 
weeks after signing the ICF, the general practitioner will 
start the intervention, and will collect the following data 
for each participating patient: demographics, comorbid-
ities, current use of psychotropic medication, (z- )BZD 
prescriptions in the last 6 months (drug name(s), quan-
tity) and a urine sample for toxicological screening.
After the baseline visit, appointments for follow- up 
(minimally one in the first six months) and prescription 
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Figure 2 Flow chart of trial procedures. BZD, benzodiazepine and zolpidem, zopiclone and zaleplon; GP, general practitioner.
general practitioner and depending on the needs of the 
patient until the end of dose reduction. This approach 
maximally reflects daily practice, as should be in a prag-
matic trial.
The general practitioners will be asked to note in the 
Electronic Health Record and eCRF the (z- )BZD- related 
interventions delivered to the patients via standardised 
entry fields at each contact with the patient, during 
6 months after baseline.
These interventions may include advice to discon-
tinue (z- )BZD, discussion of tapering schedule, discus-
sion of withdrawal symptoms, discussion of sleep quality, 
discussion of coping strategies, triggers and facilitators, 
decrease or increase of benzodiazepine dose.
Toxicological screening
At baseline, week 25 and 51, patients will be invited to 
produce a urine sample at the general practice within 
the next two weeks. For the samples of week 26 and 52, 
a reminder will be sent after one week to all participants 
who have not yet done so and every week after until a 
urine sample is obtained or the deadline is reached. The 
deadline is set at eight weeks after the first reminder.
The urine samples will be collected from the general 
practices within five days by the laboratory. Urine samples 
can be stored in a refrigerator for at least seven days 
without any effect on the toxicological screening results.
The detection window for (z- )BZDs in urine is depen-
dent on multiple factors. Using liquid chromatography–
tandem mass spectrometry (LC- MS/MS) it is typically 
6 days or longer, in case of ingestion of a single dose. 
However, chronic usage over a period of months or years 
can extend excretion times up to four to six weeks after 
cessation of use.
Currently, LC–MS/MS is the most sensitive method 
available. It is able to detect the use of low- dose (z- )BZDs, 
which are (z- )BZDs prescribed in low doses because of 
their high potency, such as flurazepam. Routinely used 
immunoassays typically have a detection level of 200 ng 
per mL as compared with 5 ng/mL for LC- MS/MS. Also, 
it is possible to detect multiple components in one assay, 
to provide quantitative results, to identify the benzodiaze-
pines exactly and to detect multiple metabolites resulting 
in longer detection periods.
All toxicological analyses will be performed at the 
laboratory AML (Algemeen Medisch Labo) in Antwerp. 
Toxicological screening of urine samples is not part of 
routine practice. Therefore, the general practitioners will 
be blinded for the results of these analyses.
data analysis
Baseline characteristics, like age, gender, relevant comor-
bidities, benzodiazepine dependence score, daily dose of 
(z- )BZD in DDD, sleep quality and Audit- C24 score, will 
be presented for the complete study population and per 
allocation arm.
Primary outcome analysis
The primary endpoint will be analysed according to the 
intention- to- treat (ITT) approach.
Logistic regression will be used for data analysis with 
benzodiazepine urine test results assessed at 12 months 
after initiation of the intervention as a binary outcome 
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A random effect will be modelled to deal with clustering 
by general practice. The group effect will be reported as 
an OR with 95% CI.
To investigate how the primary outcome behaves in 
function of age, gender, (z- )BZD dose at baseline, sleep 
quality at baseline, benzodiazepine dependency score and 
use of the e- tool (only in intervention group), subgroup 
analysis will be performed.
Secondary outcome analysis
The proportion of subjects with a negative benzodiaze-
pine urine test assessed 6 months after initiation of the 
intervention will be analysed in the same way as the 
primary endpoint.
All other secondary endpoints are binary variables, 
measured longitudinally. Analysis will be performed using 
multilevel logistic regression analysis, including random 
intercepts for patient and for general practitioner. A 
random slope for time will be modelled if beneficial for 
model fit. The fixed- effects model will include interven-
tion group, time and the group by time interaction. In 
case of a significant group by time interaction, the group 
effect will be reported separately for each time point. 
In case of a non- significant group by time interaction, a 
group main effect will be reported. The group effects will 
be presented as odds ratios with 95% CIs.
No correction for multiplicity is planned for the 
secondary analyses, as the study is not powered for these 
analyses, and hence, its results will be considered as 
hypothesis generating.
Missing data
When a patient withdraws from the study prematurely, 
all data collected up until the moment of withdrawal will 
be analysed. In case the data for measurement of the 
primary endpoint was not collected, the outcome will be 
classified as failure or continued benzodiazepine use in 
the ITT analysis. After withdrawal, no further data of this 
patient will be collected.
Economic data evaluation
One of the goals of the KCE Trials programme is to improve 
the efficiency of the healthcare system. This protocol has 
been designed with a later possible economic analysis in 
mind, that is, the necessary data to allow the conduct of 
a health economic evaluation will be collected. For more 
information on these procedures, we refer to the protocol 
of the trial.
data management
Using a trial- specific online platform, data will be auto-
matically entered in a database. These data will be gener-
ated by the general practitioners completing the eCRF 
and by the patients completing the e- questionnaires and 
using the e- tool. All collected data are stored pseudony-
mised, working with a personal study code for all patients. 
The identity of the individual patient will be blinded to 
the researchers at all times.
The collected data remain in the databases of the 
service provider and only an excerpt of this data is trans-
ferred to the data warehouse of the researchers, where it 
is merged with the results of the laboratory testing.
The data entry process will be documented, creating an 
audit trail. The database will be stored and maintained 
by the service provider, who will also be responsible for 
the pseudonymisation of patient data as trusted third 
party, compliant with the regulations of the International 
Conference on Harmonisation- Good Clinical Practice 
(ICH- GCP) and the European General Data Protection 
Regulation. Confidentiality of personal identifiable infor-
mation will be maintained throughout the trial. Data 
will be stored for a period of 25 years after the study has 
ended, according to ICH- GCP regulations.
nested study
A process evaluation will be nested within the prag-
matic cluster randomised trial. The process evaluation 
will capture data to understand how the intervention is 
used and viewed by general practitioners and patients. 
It helps interpreting the results in their context. This is 
important for informing future implementation in prac-
tice. It will explain how general practitioners and patients 
experience the intervention. With this study, we aim to 
identify factors which influence the ability (or inability) 
to withdraw from (z- )BZD in order to build a frame-
work describing the mechanisms required for successful 
implementation.
Individual interviews and focus groups will be 
conducted with general practitioners and patients taking 
part in the trial. General practitioners (approximately 8) 
will be purposively sampled to obtain variation in gender, 
language, practice setting and experience. Patients 
(approximately 14–18) will be purposively sampled 
to obtain variation in age, gender, language and how 
successful the withdrawal has been. Interviews will follow 
semistructured topic guides exploring general practi-
tioners’ and patients’ views and experiences of taking 
part in the trial. Topic guides will be informed by existing 
literature and theory of health behaviour to ensure that 
questions elicit likely key determinants of behaviour. 
Topic guides will be piloted with patient representatives 
and clinicians. Interviews and discussion groups will be 
carried out face to face and analysed using thematic and 
framework analysis.
Participant safety and monitoring
This study is considered low risk. Because no medication 
or new treatment protocols are tested, there is no addi-
tional safety reporting to the one in daily general prac-
tice. In Belgium, any adverse effects of medication can be 
reported to the federal agency for medicines and health 
products by using the yellow card. If necessary, appro-
priate measures will be taken in consultation with the 
attending general practitioner.
Close monitoring to assure proper conduct of the study 
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for general practice, in compliance with ICH- GCP regu-
lations. Moreover, annual reports of the study progress 
will be sent to the Ethics Committee of the University 
Hospital of Leuven.
dIsCussIon
In 2008, research established that computer- assisted 
tailored patient education could be a useful tool in the 
discontinuation of chronic benzodiazepine use. Ten 
Wolde et al performed a randomised controlled trial 
(RCT), showing that letters, tailored to baseline char-
acteristics of the patient, influence benzodiazepine use 
positively. After the trial, the most successful intervention, 
being a single customised letter, was published online 
in a password- protected environment to reach as many 
patients as possible.29 No further research on the effec-
tiveness of this online module has been published.
Currently, this is the only (English) publication on 
computer- assisted patient education for discontinuation 
of chronic benzodiazepine use. This means that our 
trial will be the first RCT that assesses the superiority of 
blended care over usual care for (z- )BZD discontinuation 
in primary care.
Moreover, the Big Bird trial is innovative in its meth-
odology. In most discontinuation studies, researchers 
use self- reported data from patients and/or general 
practitioners to assess the success of an intervention. In 
this trial, success rate will depend on the proportion of 
patients that has discontinued their use of (z- )BZD as 
assessed by toxicological screening of urine samples at 12 
months after start of the intervention. This measurement 
is also performed at 6 months, when access to the online 
platform has just ended.
Some might argue that delivering urine samples will 
trigger patients to increase their efforts for discontinuing 
(z- )BZD. To limit this possibility, we have taken precau-
tionary measures by not communicating the results of the 
toxicological screening to the general practitioner, nor to 
the patient.
The toxicological analysis of urine samples will enable us 
to compare the concentrations of (z- )BZD with the reports 
of patients and general practitioners and provide insights 
on the reliability of self- reporting in studies on discon-
tinuation. So, although the prescription information is 
not extracted automatically, the report of prescribed (z- )
BZD use by the general practitioner in the eCRF contains 
valuable information to establish a proxy of the (z- )BZD 
intake per patient. Another strength of this study is the 
collaboration between six universities, which enables us 
to implement the intervention across the Belgian French- 
speaking and Dutch- speaking population.
However, due to language and the technological 
character of the intervention, some vulnerable groups 
of patients cannot be reached. Language restrictions 
exclude the German community in Belgium and a 
number of migrant groups from participation. Also, non- 
e- literate patients, including elderly people who are not 
familiar with internet usage but who report high (z- )BZD 
intake, cannot take part in the trial. This is unfortunate as 
these patients could also benefit from more psychosocial 
support and counselling about medication use. If effec-
tive, we need to consider adapting the existing materials 
for use with these patients.
Finally, although the focus in the trial is on the effect of 
blended care, the implementation of such an approach is 
also evaluated, which will provide valuable knowledge for 
further eHealth developments in primary care.
EthICs And dIssEMInAtIon
This study will be conducted in accordance with the prin-
ciples outlined in the Declaration of Helsinki (seventh 
revision). Any substantial protocol amendments will be 
submitted to the ethics committee.
The study results will be disseminated via open- access, 
peer- reviewed publications and conference presentations.
trial status
Currently, recruitment of general practitioners and 
patients is ongoing. First patient first visit is expected in 
August 2019. Last patient last visit is expected in September 
2020. Database lock will take place in November 2020.
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